further to stomach paralysis, the medicinal drugs have been related to an multiplied risk of pancreatitis (pancreatic infection) and intestinal obstruction
which stops meals from transferring through the small or huge intestine, consistent with the assertion.
Over a 14-year period (among 2006 and 2020), UBC researchers reviewed the health insurance claim statistics of approximately sixteen million U.S. patients who were prescribed Ozempic, Wegovy, or both semaglutide or liraglutide pills.
people who used a GLP-1 agonist had been three.sixty seven times much more likely to get stomach paralysis
9.09 times more likely to broaden pancreatitis, and four.22 instances more likely to have bowel blockage when as compared to individuals who took every other weight reduction medication, bupropion-naltrexone.
Although these complications were rare, the researchers found them concerning, given that millions of people are using these medications worldwide.
The number of people in the U.S. using GLP-1 agonists for either diabetes or obesity reached 40 million in 2022, they noted.
"These drugs are becoming increasingly accessible, and it is concerning that, in some cases, people can simply go online
order these kinds of medications when they may not have a full understanding of what could potentially happen," said first author Mohit Sodhi, a graduate of UBC’s experimental medicine program, in the release.